SALT LAKE CITY, March 07, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in
the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic
treatments, announces that Juneau Biosciences will deliver four scienctific presentations at the 66th Annual Meeting of
the Society for Reproductive Investigation (SRI), which will be held from Tuesday, March 12th to Saturday, March,
16th in Paris, France. Predictive Technology Group inlicensed the technology supporting its ARTGuide®
Test for endometriosis and other genetic causes of infertility from Juneau and is the company’s largest shareholder.
Juneau Biosciences scientists, Kenneth Ward, M.D. and Hans Albertsen, Ph.D., will discuss Juneau’s recent findings concerning
the genetics of endometriosis.
SRI is the leading international research organization in the areas of gynecology and reproductive health. The
organization seeks to advance reproductive and women's health care through outstanding basic, translational, and clinical science
and by training and mentoring future generations of investigators.
Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, recently launched its novel test for women
experiencing infertility, called ARTGuide®, to selected Beta launch centers. The ARTGuide® Test will
now incorporate these latest data. The test is expected to change the way that Advanced Reproductive Technologies (ART) such
as In Vitro Fertilization (IVF) are used to help couples struggling to have a baby. Tens of thousands of women have been tested as
part of this research and development program.
About Endometriosis:
Endometriosis affects more than 10 million women in the United States. Endometriosis occurs when the tissue similar to the lining
of the uterus (womb), found in other parts of the body, most commonly in the pelvis. Monthly bleeding and inflammation caused by
these lesions may severely impact a woman's quality of life. Some affected women experience severe pain, others infertility, others
problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the
difficulties, invasiveness, and expense of diagnosing the condition, the majority of women diagnosed with endometriosis suffer for
over a decade before receiving treatment. Treatment may involve hormonal suppression or a targeted destruction of the abnormal
tissue during surgery.
About Juneau Biosciences:
Juneau Biosciences is a privately held medical genetics company conducting groundbreaking research to develop innovative diagnostic
products for diseases that predominantly affect women. Launched in early 2007, the Salt Lake City based firm has focused so far on
the development of novel molecular diagnostics and therapeutics for endometriosis, a condition estimated to affect approximately
10% of reproductive-age females.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and
companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive
Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue
products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that
assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.
Additional information is available at Predtechgroup.com; Predrx.com and Predictivebiotech.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially
forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and
demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new
product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional
intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may
identify from time to time in the future.
Contact:
Investors
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
